Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.

Zhang, Linlin; Chen, Liang; Yu, Hao

Zhang, Linlin; Chen, Liang; Yu, Hao.

Affiliation

Zhang L; Department of Obstetrics and Gynecology, Shandong Maternity and Child Health Care Hospital, 238 Jingshidong Road, Jinan, 250014, People's Republic of China.
Chen L; Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, 250117, People's Republic of China.
Yu H; Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, 250117, People's Republic of China. fishdoctor@yeah.net.

Invest New Drugs ; 38(4): 1186-1191, 2020 08.

Article in En | MEDLINE | ID: mdl-31637668

Subject(s)
Key words

Apatinib; Cervical cancer; Recurrence; Systemic therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Protein-Tyrosine Kinases / Uterine Cervical Neoplasms / Angiogenesis Inhibitors / Protein Kinase Inhibitors / Neoplasm Recurrence, Local / Neovascularization, Pathologic Limits: Adult / Female / Humans / Middle aged Language: En Journal: Invest New Drugs Year: 2020 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google